Search | Clinical Trials Finder

Conditions: Healthy Volunteers
Interventions: [14C] BMS-986278, Kinevac®; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 21 Years to 65 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: BRAF NP_004324.2:p.V600X, KRAS wt Allele, Metastatic Malignant Solid Neoplasm, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Unresectable Solid Neoplasm
Interventions: Cetuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Vemurafenib; Biological · Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Childhood CNS Tumor
Interventions: SGT-53, Radiation, Irinotecan, Temozolomide, Bevacizumab; Genetic · Radiation · Drug
Lead sponsor: SynerGene Therapeutics, Inc.; Industry
Eligibility: 1 Year to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Type 2 Diabetes
Interventions: Insulin Glargine, Metformin, Prandial insulin, Exenatide; Drug
Lead sponsor: University of Washington; Other
Eligibility: 40 Years to 75 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 12
States / cities: San Diego, California • Miami, Florida • Atlanta, Georgia + 9 more

Conditions: Lymphoma
Interventions: Carmustine, Etoposide, Cytarabine, Melphalan, Rituximab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 80 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: End Stage Renal Disease
Interventions: Nutritional Supplement; Dietary Supplement
Lead sponsor: Dialysis Clinic, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10,457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Jacksonville, Florida • Nashville, Tennessee

Conditions: Xerostomia, Sjogren Syndrome, Dry Mouth
Interventions: MighTeaFlow, Xylitol; Dietary Supplement
Lead sponsor: Augusta University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Brain and Central Nervous System Tumors, Kidney Cancer, Liver Cancer, Retinoblastoma, Sarcoma
Interventions: filgrastim, busulfan, etoposide, ifosfamide, melphalan, thiotepa, stem cell transplantation, tomotherapy, total marrow irradiation, Mesna, Whole lung radiation; Biological · Drug · Procedure + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy
Interventions: Recombinant human hyaluronidase PH20 (rHuPH20), Insulin lispro, Insulin glulisine, Insulin aspart; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Recurrent Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Melanoma Stage III
Interventions: [203Pb]VMT01, [212Pb]VMT01, Nivolumab; Drug
Lead sponsor: Perspective Therapeutics; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 13
States / cities: Orange, California • Jacksonville, Florida • Miami, Florida + 9 more

Conditions: Head and Neck Cancer
Interventions: bevacizumab, cisplatin, conventional surgery, intensity-modulated radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Low Back Pain, Pain
Interventions: D-cycloserine, placebo; Drug
Lead sponsor: Thomas J. Schnitzer; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Non Small Cell Lung Cancer
Interventions: eribulin mesylate, pemetrexed, Eribulin mesylate (eribulin; E7389); Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 6
States / cities: Tucson, Arizona • Denver, Colorado • Fort Myers, Florida + 3 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Amivantamab, Pemetrexed, Carboplatin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 17
States / cities: Duarte, California • Orange, California • Santa Monica, California + 13 more

Conditions: Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma
Interventions: RGX-104, Ipilimumab, Docetaxel, Pembrolizumab, Carboplatin, Pemetrexed; Drug
Lead sponsor: Inspirna, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 21
States / cities: Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 16 more

Conditions: Non-small Cell Lung Cancer
Interventions: canakinumab, canakinumab-matching placebo, pembrolizumab, carboplatin, cisplatin, paclitaxel, nab-paclitaxel, pemetrexed; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 673 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 4
States / cities: Long Beach, California • Los Angeles, California • Orlando, Florida + 1 more

Conditions: Congenital Amegakaryocytic Thrombocytopenia, Diamond-blackfan Anemia, Leukemia, Myelodysplastic Syndromes, Severe Congenital Neutropenia
Interventions: alemtuzumab, busulfan, cyclosporine, fludarabine phosphate, methotrexate, methylprednisolone, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, umbilical cord blood transplantation; Biological · Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: Up to 21 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 2
States / cities: San Francisco, California • Madison, Wisconsin

Conditions: High Grade Glioma
Interventions: 5 Aminolevulinic Acid, CV01-delivered ultrasound; Drug · Device
Lead sponsor: Alpheus Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: St Louis, Missouri • Amherst, New York • Lake Success, New York

Conditions: Crohn's Disease
Interventions: Adalimumab, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 48
States / cities: Birmingham, Alabama • Dothan, Alabama • La Jolla, California + 41 more

Conditions: Solid Tumors
Interventions: Regorafenib, (Stivarga, BAY73-4506), Nivolumab (Opdivo); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: Duarte, California • Aurora, Colorado • Tampa, Florida + 3 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, No Prior Chemotherapy
Interventions: Paclitaxel, Carboplatin, Bevacizumab; Drug
Lead sponsor: David O'Malley; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2023
U.S. locations: 1
States / cities: Hilliard, Ohio

Conditions: Insulin Resistance, Hyperinsulinemia, Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
Interventions: Insulin human, Octreotide Acetate, Glucagon, Growth Hormone, Human, 20% D-glucose (aq), [6,6-2H2] D-glucose, [1-13C1] sodium acetate, Nestle BOOST Plus, KIND Bar, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer; Drug · Diagnostic Test · Dietary Supplement + 1 more
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Cancer
Interventions: bevacizumab, fluorouracil, leucovorin calcium, oxaliplatin; Biological · Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years to 120 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Fatigue Syndrome, Orthostatic Intolerance, Postural Tachycardia Syndrome
Interventions: Autonomic Function Testing, Saline infusions, L-NMMA trimethaphan, methyldopa; Other · Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male Participants

Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

SGT-53 in Children With Recurrent or Progressive CNS Malignancies

FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies

Health Effects of oraL Protein Supplements in HD (The HELPS-HD Trial)

Green Tea Lozenges for the Management of Dry Mouth

MT2004-30: Tomotherapy for Solid Tumors

A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

D-cycloserine in the Management of Chronic Low Back Pain

Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer

A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects

Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders

Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer

Human Models of Selective Insulin Resistance: Pancreatic Clamp

MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer

Autonomic Nervous System and Chronic Fatigue Syndrome